Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

A significant disconnect exists between the FDA leadership's public statements promoting flexibility and the stringent, delay-prone reality faced by companies. For areas like gene therapy, firms report feeling the "rug was pulled out," suggesting investors should be skeptical of the agency's accommodating PR.

The FDA issued Complete Response Letters for both REGENXBIO's gene therapy and DISC Medicine's oral drug, signaling high scrutiny for accelerated approvals. The agency specifically cited concerns over the relevance of surrogate endpoints and required more robust clinical trial data, highlighting the risks of relying on non-traditional approval pathways.

Replimune's core argument against the FDA's rejection is that the entire melanoma medical community is demanding access to their drug. The company highlights that 22 trial investigators and major medical institutions wrote letters to the FDA, attempting to use the weight of expert opinion to overrule the regulator's objections.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

The FDA advised against a single-arm study unless data was "sufficiently compelling." Replimune argues the FDA's subsequent actions—granting priority review and not objecting to the filing—implied the data met this bar, making the final rejection based on the study design feel disingenuous and like a retrospective goalpost shift.

The FDA's second Complete Response Letter for Replimune's advanced melanoma drug is a disappointing signal for the industry. Despite having what appeared to be a decent risk-benefit profile, the rejection suggests the regulatory bar for approvals based on single-arm studies remains unpredictably high and a head-scratcher for observers.

A primary driver of recent pharma launch failures is underinvestment in pre-launch market conditioning. Cautious investors and tighter budgets mean companies have fewer resources to tell their scientific story effectively before launch. This delayed and underfunded approach has a dramatic negative impact on commercial success.

The FDA's inconsistency and the growing gap between its guidance and actions have made regulatory risk a primary evaluation factor for investors, complicating trial design, causing delays, and raising the cost of capital for biotechs.